keyword
Keywords targeted therapy for glioblast...

targeted therapy for glioblastoma multiforme

https://read.qxmd.com/read/38523681/coactosin-like-protein-1-cotl1-could-be-an-immunological-and-prognostic-biomarker-from-pan-cancer-analysis-to-low-grade-glioma-validation
#1
JOURNAL ARTICLE
Xiaoyun Wang, Yuwei Bai, Bei Wang
BACKGROUND: Cancer represents a widespread global health challenge impacting millions of individuals worldwide. Identifying new targets for cancer treatment is a crucial step in developing more effective therapies. Among these potential targets, Coactosin-like protein 1 (COTL1), a cytoskeleton-associated protein with critical roles in cell migration, adhesion, and signaling, has shown involvement in tumor progression. METHODS: GSCA, TIMER, SangerBox database were used to explore the COTL1 expression across different tumor types...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38522697/harnessing-the-potential-of-nanoengineered-sirnas-carriers-for-target-responsive-glioma-therapy-recent-progress-and-future-opportunities
#2
REVIEW
Kailash Ahirwar, Ankit Kumar, Nidhi Srivastava, Shubhini A Saraf, Rahul Shukla
Past scientific testimonials in the field of glioma research, the deadliest tumor among all brain cancer types with the life span of 10-15 months after diagnosis is considered as glioblastoma multiforme (GBM). Even though the availability of treatment options such as chemotherapy, radiotherapy, and surgery, are unable to completely cure GBM due to tumor microenvironment complexity, intrinsic cellular signalling, and genetic mutations which are involved in chemoresistance. The blood-brain barrier is accountable for restricting drugs entry at the tumor location and related biological challenges like endocytic degradation, short systemic circulation, and insufficient cellular penetration lead to tumor aggression and progression...
March 22, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38509672/metabotropic-glutamate-receptors-type-3-and-5-feature-the-neurotransmitter-type-of-glioblastoma-a-bioinformatic-approach
#3
JOURNAL ARTICLE
Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella
BACKGROUND: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal. OBJECTIVE: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine. METHODS: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas...
March 20, 2024: Current Neuropharmacology
https://read.qxmd.com/read/38505170/nanoparticle-based-combinational-strategies-for-overcoming-the-blood-brain-barrier-and-blood-tumor-barrier
#4
REVIEW
Su Hyun Lim, Gi Taek Yee, Dongwoo Khang
The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor prognosis. Nanoparticle-based combinational strategies have emerged as promising modalities to overcome these barriers and enhance drug penetration into the brain parenchyma. This review discusses various nanoparticle-based combinatorial approaches that combine nanoparticles with cell-based drug delivery, viral drug delivery, focused ultrasound, magnetic field, and intranasal drug delivery to enhance drug permeability across the BBB and BTB...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38500293/comprehensive-analysis-of-histone-acetylation-related-genes-in-glioblastoma-and-lower-grade-gliomas-insights-into-drug-sensitivity-molecular-subtypes-immune-infiltration-and-prognosis
#5
JOURNAL ARTICLE
Jiajun Qin, Jin Fu, Xianzhen Chen
OBJECTIVES: The purpose of this research was to study the impact of histone acetylation on glioblastoma multiforme (GBM) and lower-grade gliomas (LGG) and its potential implications for patient prognosis. We aimed to assess the histone acetylation score (HAs) and its relationship with key genes involved in histone acetylation regulation. METHOD: The TCGA-GBMLGG dataset, which provides comprehensive genomic and clinical information, was utilized for this study. We calculated the HAs by analyzing the expression levels of histone acetylation-related genes, including histone acetyltransferases and histone deacetylases, in GBM and LGG patients...
March 2024: Journal of Gene Medicine
https://read.qxmd.com/read/38486856/advancements-in-chimeric-antigen-receptor-expressing-t-cell-therapy-for-glioblastoma-multiforme-literature-review-and-future-directions
#6
REVIEW
Michael Goutnik, Alexandria Iakovidis, Megan E H Still, Rachel S F Moor, Kaitlyn Melnick, Sandra Yan, Muhammad Abbas, Jianping Huang, Ashley P Ghiaseddin
Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies. CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM...
2024: Neuro-oncology advances
https://read.qxmd.com/read/38474286/glioblastoma-an-update-in-pathology-molecular-mechanisms-and-biomarkers
#7
REVIEW
Zhong Lan, Xin Li, Xiaoqin Zhang
Glioblastoma multiforme (GBM) is the most common and malignant type of primary brain tumor in adults. Despite important advances in understanding the molecular pathogenesis and biology of this tumor in the past decade, the prognosis for GBM patients remains poor. GBM is characterized by aggressive biological behavior and high degrees of inter-tumor and intra-tumor heterogeneity. Increased understanding of the molecular and cellular heterogeneity of GBM may not only help more accurately define specific subgroups for precise diagnosis but also lay the groundwork for the successful implementation of targeted therapy...
March 6, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473710/use-of-micrornas-as-diagnostic-prognostic-and-therapeutic-tools-for-glioblastoma
#8
REVIEW
David Valle-Garcia, Verónica Pérez de la Cruz, Itamar Flores, Aleli Salazar, Benjamín Pineda, Karla F Meza-Sosa
Glioblastoma (GB) is the most aggressive and common type of cancer within the central nervous system (CNS). Despite the vast knowledge of its physiopathology and histology, its etiology at the molecular level has not been completely understood. Thus, attaining a cure has not been possible yet and it remains one of the deadliest types of cancer. Usually, GB is diagnosed when some symptoms have already been presented by the patient. This diagnosis is commonly based on a physical exam and imaging studies, such as computed tomography (CT) and magnetic resonance imaging (MRI), together with or followed by a surgical biopsy...
February 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473623/designing-gold-nanoparticles-for-precise-glioma-treatment-challenges-and-alternatives
#9
REVIEW
Cedric Lansangan, Menka Khoobchandani, Ruchit Jain, Serge Rudensky, Christopher C Perry, Rameshwar Patil
Glioblastoma multiforme (GBM) is a glioma and the most aggressive type of brain tumor with a dismal average survival time, despite the standard of care. One promising alternative therapy is boron neutron capture therapy (BNCT), which is a noninvasive therapy for treating locally invasive malignant tumors, such as glioma. BNCT involves boron-10 isotope capturing neutrons to form boron-11, which then releases radiation directly into tumor cells with minimal damage to healthy tissues. This therapy lacks clinically approved targeted blood-brain-barrier-permeating delivery vehicles for the central nervous system (CNS) entry of therapeutic boron-10...
March 1, 2024: Materials
https://read.qxmd.com/read/38471271/exploring-the-gut-microbiota-and-its-potential-as-a-biomarker-in-gliomas
#10
REVIEW
Dana Aljarrah, Naima Chalour, Amine Zorgani, Tracy Nissan, Md Zahidul I Pranjol
Gut microbiome alterations are associated with various cancers including brain tumours such as glioma and glioblastoma. The gut communicates with the brain via a bidirectional pathway known as the gut-brain axis (GBA) which is essential for maintaining homeostasis. The gut microbiota produces many metabolites including short chain fatty acids (SCFAs) and essential amino acids such as glutamate, glutamine, arginine and tryptophan. Through the modulation of these metabolites the gut microbiome is able to regulate several functions of brain cells, immune cells and tumour cells including DNA methylation, mitochondrial function, the aryl hydrocarbon receptor (AhR), T-cell proliferation, autophagy and even apoptosis...
March 11, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38468932/uncovering-the-subtype-specific-disease-module-and-the-development-of-drug-response-prediction-models-for-glioma
#11
JOURNAL ARTICLE
Sana Munquad, Asim Bikas Das
The poor prognosis of glioma patients brought attention to the need for effective therapeutic approaches for precision therapy. Here, we deployed algorithms relying on network medicine and artificial intelligence to design the framework for subtype-specific target identification and drug response prediction in glioma. We identified the driver mutations that were differentially expressed in each subtype of lower-grade glioma and glioblastoma multiforme and were linked to cancer-specific processes. Driver mutations that were differentially expressed were also subjected to subtype-specific disease module identification...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38442508/oncolytic-viral-therapy-for-gliomas-advances-in-the-mechanisms-and-approaches-to-delivery
#12
REVIEW
A Romanishin, A Vasilev, E Khasanshin, A Evtekhov, E Pusynin, K Rubina, V Kakotkin, M Agapov, E Semina
Glioma is a diverse category of tumors originating from glial cells encompasses various subtypes, based on the specific type of glial cells involved. The most aggressive is glioblastoma multiforme (GBM), which stands as the predominant primary malignant tumor within the central nervous system in adults. Despite the application of treatment strategy, the median survival rate for GBM patients still hovers around 15 months. Oncolytic viruses (OVs) are artificially engineered viruses designed to selectively target and induce apoptosis in cancer cells...
May 2024: Virology
https://read.qxmd.com/read/38439834/gene-therapy-in-glioblastoma-multiforme-can-it-be-a-role-changer
#13
REVIEW
Mohammad Rayati, Vahid Mansouri, Naser Ahmadbeigi
Glioblastoma multiforme (GBM) is one of the most lethal cancers with a poor prognosis. Over the past century since its initial discovery and medical description, the development of effective treatments for this condition has seen limited progress. Despite numerous efforts, only a handful of drugs have gained approval for its treatment. However, these treatments have not yielded substantial improvements in both overall survival and progression-free survival rates. One reason for this is its unique features such as heterogeneity and difficulty of drug delivery because of two formidable barriers, namely the blood-brain barrier and the tumor-blood barrier...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38416873/angiopep-2-functionalized-lipid-cubosomes-for-blood-brain-barrier-crossing-and-glioblastoma-treatment
#14
JOURNAL ARTICLE
Xudong Cai, Ahmed Refaat, Poh-Yi Gan, Bo Fan, Haitao Yu, San H Thang, Calum J Drummond, Nicolas H Voelcker, Nhiem Tran, Jiali Zhai
Glioblastoma multiforme (GBM) is an aggressive brain cancer with high malignancy and resistance to conventional treatments, resulting in a bleak prognosis. Nanoparticles offer a way to cross the blood-brain barrier (BBB) and deliver precise therapies to tumor sites with reduced side effects. In this study, we developed angiopep-2 (Ang2)-functionalized lipid cubosomes loaded with cisplatin (CDDP) and temozolomide (TMZ) for crossing the BBB and providing targeted glioblastoma therapy. Developed lipid cubosomes showed a particle size of around 300 nm and possessed an internal ordered inverse primitive cubic phase, a high conjugation efficiency of Ang2 to the particle surface, and an encapsulation efficiency of more than 70% of CDDP and TMZ...
February 28, 2024: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/38398131/theranostic-uses-of-the-heme-pathway-in-neuro-oncology-protoporphyrin-ix-ppix-and-its-journey-from-photodynamic-therapy-pdt-through-photodynamic-diagnosis-pdd-to-sonodynamic-therapy-sdt
#15
REVIEW
Stuart L Marcus, Mark P de Souza
ALA PDT, first approved as a topical therapy to treat precancerous skin lesions in 1999, targets the heme pathway selectively in cancers. When provided with excess ALA, the fluorescent photosensitizer PpIX accumulates primarily in cancer tissue, and ALA PDD is used to identify bladder and brain cancers as a visual aid for surgical resection. ALA PDT has shown promising anecdotal clinical results in recurrent glioblastoma multiforme. ALA SDT represents a noninvasive way to activate ALA PDT and has the potential to achieve clinical success in the treatment of both intracranial and extracranial cancers...
February 10, 2024: Cancers
https://read.qxmd.com/read/38391976/in-vitro-glioblastoma-model-on-a-plate-for-localized-drug-release-study-from-a-3d-printed-drug-eluted-hydrogel-mesh
#16
JOURNAL ARTICLE
Behnad Chehri, Kaiwen Liu, Golnaz Vaseghi, Amir Seyfoori, Mohsen Akbari
Glioblastoma multiforme (GBM) is an aggressive type of brain tumor that has limited treatment options. Current standard therapies, including surgery followed by radiotherapy and chemotherapy, are not very effective due to the rapid progression and recurrence of the tumor. Therefore, there is an urgent need for more effective treatments, such as combination therapy and localized drug delivery systems that can reduce systemic side effects. Recently, a handheld printer was developed that can deliver drugs directly to the tumor site...
February 19, 2024: Cells
https://read.qxmd.com/read/38358804/cathepsin-b-responsive-programmed-brain-targeted-delivery-system-for-chemo-immunotherapy-combination-therapy-of-glioblastoma
#17
JOURNAL ARTICLE
Shaoping Jiang, Wenpei Li, Jun Yang, Tian Zhang, Yuquan Zhang, Lin Xu, Bo Hu, Zhi Li, Huile Gao, Yuanyu Huang, Shaobo Ruan
Tumor-associated macrophages (TAMs) are closely related to the progression of glioblastoma multiform (GBM) and its development of therapeutic resistance to conventional chemotherapy. TAM-targeted therapy combined with conventional chemotherapy has emerged as a promising strategy to combat GBM. However, the presence of the blood-brain barrier (BBB) severely limits the therapeutic efficacy. Meanwhile, the lack of ability to distinguish different targeted cells also poses a challenge for precise therapy. Herein, we propose a cathepsin B (CTSB)-responsive programmed brain-targeted delivery system (D&R-HM-MCA) for simultaneous TAM-targeted and GBM-targeted delivery...
February 15, 2024: ACS Nano
https://read.qxmd.com/read/38357955/effects-of-hsv-g47%C3%AE-oncolytic-virus-on-telomerase-and-telomere-length-alterations-in-glioblastoma-multiforme-cancer-stem-cells-under-hypoxia-and-normoxia-conditions
#18
JOURNAL ARTICLE
Reza Vazifehmand, Dhuha Saeed Ali, Foroozandeh Monem Homaie, Fateme Molaei Jalalvand, Zulkefley Othman, Chau Deming, Johnson Stanslas, Zamberi Sekawi
BACKGROUND: Due to the existence of tumor stem cells with tumorigenicity properties and resistance patterns, treatment of glioblastoma is not easy. Hypoxia is a major concern in glioblastoma therapy. Telomerase activity and telomere length alterations have been known to play a critical role in glioblastoma progression and invasion. OBJECTIVE: This study aimed to investigate the effects of HSV-G47Δ oncolytic virus on telomerase and telomere length alterations in U251GBMCSCs (U251-Glioblastoma cancer stem cells) under hypoxia and normoxia conditions...
February 13, 2024: Current Cancer Drug Targets
https://read.qxmd.com/read/38349262/early-investigation-of-a-novel-si306-theranostic-prodrug-for-glioblastoma-treatment
#19
JOURNAL ARTICLE
Chiara Vagaggini, Debora Petroni, Ilaria D'Agostino, Federica Poggialini, Chiara Cavallini, Annarita Cianciusi, Annalisa Salis, Lucia D'Antona, Valeria Francesconi, Fabrizio Manetti, Gianluca Damonte, Francesca Musumeci, Luca Menichetti, Elena Dreassi, Anna Carbone, Silvia Schenone
Glioblastoma multiforme (GBM) is one of the most aggressive malignancies with a high recurrence rate and poor prognosis. Theranostic, combining therapeutic and diagnostic approaches, arises as a successful strategy to improve patient outcomes through personalized medicine. Src is a non-receptor tyrosine kinase (nRTK) whose involvement in GBM has been extensively demonstrated. Our previous research highlighted the effectiveness of the pyrazolo[3,4-d]pyrimidine SI306 and its more soluble prodrug CMP1 as Src inhibitors both in in vitro and in vivo GBM models...
February 2024: Drug Development Research
https://read.qxmd.com/read/38318212/c-myc-h19-mir-29b-axis-downregulates-nerve-glial-ng-2-expression-in-glioblastoma-multiforme
#20
JOURNAL ARTICLE
Anne S Boewe, Selina Wrublewsky, Jessica Hoppstädter, Claudia Götz, Alexandra K Kiemer, Michael D Menger, Matthias W Laschke, Emmanuel Ampofo
Nerve/glial antigen (NG)2 is highly expressed in glioblastoma multiforme (GBM). However, the underlying mechanisms of its upregulated expression are largely unknown. In silico analyses reveal that the tumor-suppressive miR-29b targets NG2. We used GBM-based data from The Cancer Genome Atals databases to analyze the expression pattern of miR-29b and different target genes, including NG2. Moreover, we investigated the regulatory function of miR-29b on NG2 expression and NG2-related signaling pathways. We further studied upstream mechanisms affecting miR-29b-dependent NG2 expression...
March 12, 2024: Molecular Therapy. Nucleic Acids
keyword
keyword
97845
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.